Background The BEYOND trial found that the addition of bevacizumab (B) to paclitaxel–
carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients …

Background The first-line bevacizumab plus chemotherapy resulted in a clinical efficacy for
Chinese patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). Some …

Objective: To investigate whether LY01008, a locally developed bevacizumab biosimilar
agent, is appropriate for widespread use among Chinese advanced or recurrent …

Background In patients with advanced-stage non–small-cell lung cancer (NSCLC) with
nonsquamous histology, bevacizumab maintenance therapy after initial combination with …

Background Delivering affordable cancer care is becoming increasingly important.
Bevacizumab (BEV) is a costly molecular targeted agent effective for a variety of cancer …

Aims: The aim of this analysis is to investigate the mean incremental costs and life
expectancy associated with two first‐line treatments for advanced non‐squamous non‐small …

Objective: There are two new treatment options available for the treatment of
adenocarcinoma histology non-small cell lung cancer (NSCLC) which offer improved benefit …

Objectives Bevacizumab is approved for treatment of advanced non-small cell lung cancer
(NSCLC) in combination with chemotherapy based on a 2-month median survival benefit …

Introduction The Eastern Cooperative Oncology Group (ECOG) 4599 study showed a
significant survival benefit with the use of bevacizumab (BV) in combination with carboplatin …

We present the treatment rationale and study design of the AvaALL (MO22097;
ClinicalTrials: NCT01351415) trial, a multicenter, open-label, randomized, two-arm, phase …